As Healthcare Leader Exits, Bayer’s Pharma Business Quietly Thrives
This article was originally published in The Pink Sheet Daily
Executive Summary
While Bayer’s pharmaceutical business, tucked into an enormous conglomerate, sometimes flies under the radar of investors, it has had a strong year. The group that Jorg Reinhardt is leaving should continue to thrive, as it is buttressed by new product launches such as anti-coagulant Xarelto, a big presence in emerging markets, a full pipeline, and limited exposure to generic competition, analysts say.